Clinical trial
Open Label Arimidex in Gynecomastia
NCT00241436 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00241436 |
|---|---|
| Title | Open Label Arimidex in Gynecomastia |
| Official title | An Open-Label Pharmacokinetic and Pharmacodynamic Study of Anastrozole (Arimidex™) Used to Treat Pubertal Boys With Gynecomastia of Recent Onset |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Gynecomastia |
| Intervention type | Drug |
| Interventions | Anastrozole (ARIMIDEX™) |
| Enrollment | 35 |
| Start date | Jun 1, 2005 |
| Primary completion | Nov 1, 2006 |
| Completion | Nov 1, 2006 |
| First posted | Oct 19, 2005 |
| Last update posted | Jan 27, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: